The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Apellis Pharmaceuticals Inc’s current trading price is -54.67% away from its 52-week high, while its distance from the 52-week low is 37.43%. The stock’s price range for this period has been between $24.34 and $73.80 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 5.05 million for the day, a number notably higher than the average daily volume of 3.14 million over the last three months.
Apellis Pharmaceuticals Inc experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $73.80 on 01/09/24, while the lowest price for the same period was registered at $24.34 on 11/05/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Apellis Pharmaceuticals Inc (APLS) has experienced a quarterly decline of -18.51% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 4.16B and boasts a workforce of 706 employees.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 33.13, with a change in price of -7.70. Similarly, Apellis Pharmaceuticals Inc recorded 2,577,307 in trading volume during the last 100 days, posting a change of -18.71%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for APLS stands at 1.98. Similarly, the long-term debt-to-equity ratio is also 1.96.
APLS Stock Stochastic Average
Apellis Pharmaceuticals Inc’s raw stochastic average for the past 50 days is presently 81.41%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 78.71%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 85.45% and 90.73%, respectively.
APLS Stock Price Performance Analysis
The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. The index has shown a price loss of -44.12% this year. Over the last six months, there has been a stronger performance of -18.51%. The price of APLS fallen by 19.15% during the last 30 days period. For the last 5-days stocks have slided -2.02%.
